Product Data Sheet

Product Name: RJS308 TFA
Cat. No.: GC80941

Chemical Properties

Cas. No.

Formula	$C_{65}H_{76}F_3N_{13}O_{13}S$	M.Wt	1336.44
Solubility	DMSO: 100 mg/mL (74.83 mM; Need ultrasonic)	Storage	Store at 4°C, away from moisture and light
General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		

Structure



Background

RJS308 TFA is a selective Cyclophilin A (CypA) PROTAC degrader. RJS308 TFA induces ubiquitin-

dependent CypA degradation by recruiting the VHL E3 ligase complex, and forms a ternary complex with CypA and VHL/elongin C/elongin B. RJS308 TFA exhibits anti- HIV-1 and anti- HCV activities. RJS308 TFA can be used in studies related to viral infections [1]. (Pink: Cyclophilin A ligand; Blue: VHL ligand; Black: linker).

In Vitro, RJS308 TFA binds to recombinant full-length human CypA in SPR binding assays with a KD value of 108 nM, and also binds to N-terminally truncated human CypB with a KD value of 320 nM[1]. RJS308 TFA (0.01-10 μM; 0-6 days) degrades CypA in Jurkat cells[1]. RJS308 TFA (1-5 μM; 48 h) exhibits anti-HIV-1 activity in primary activated human CD4+ T cells, and this activity depends on VHL-mediated CypA degradation[1]. RJS308 TFA (1-5 μM; 48 h) exhibits anti-HCV activity in Huh7 human hepatocellular carcinoma cells, and this activity depends on VHL-mediated CypA degradation[1].

References:
[1]. Newton LS, et al., Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV. Nat Commun. 2025 Feb 10;16(1):1484.